Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hampel

Showing results (11-20 of 411) with videos related to

Pageof 42
Sort By:
Clinical Chemistry and Laboratory Medicine|February 24, 2011
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's diseaseDavid Prvulovic, Harald Hampel
Dementia and Geriatric Cognitive Disorders|June 5, 2004
Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementiaHarald Hampel, Stefan J Teipel
Behavior Genetics|February 18, 2006
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's diseaseStefan J Teipel, Harald Hampel
Brain Research Bulletin|August 12, 2003
Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau proteinHarald Hampel, Alexander Goernitz, Katharina Buerger
Progress in Neurobiology|September 28, 2011
Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirementsKarl Broich, Marco Weiergräber, Harald Hampel
Molecular Diagnosis & Therapy|June 1, 2011
Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potentialCarmen Noelker, Harald Hampel, Richard Dodel
Neuropsychiatric Disease and Treatment|June 4, 2010
Optimal management of Alzheimer's disease patients: Clinical guidelines and family adviceJulia Haberstroh, Harald Hampel, Johannes Pantel
CNS Neuroscience & Therapeutics|October 21, 2009
Biological marker candidates of Alzheimer's disease in blood, plasma, and serumPhiline Schneider, Harald Hampel, Katharina Buerger
Expert Opinion on Drug Metabolism & Toxicology|February 2, 2010
Galantamine for Alzheimer's diseaseDavid Prvulovic, Harald Hampel, Johannes Pantel
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 27, 2013
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's diseaseKaj Blennow, Harald Hampel, Henrik Zetterberg
Pageof 42

Showing results (11-20 of 411) with videos related to

Sort By:
Pageof 42
Clinical Chemistry and Laboratory Medicine|February 24, 2011
Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's diseaseDavid Prvulovic, Harald Hampel
Dementia and Geriatric Cognitive Disorders|June 5, 2004
Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementiaHarald Hampel, Stefan J Teipel
Behavior Genetics|February 18, 2006
Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer's diseaseStefan J Teipel, Harald Hampel
Brain Research Bulletin|August 12, 2003
Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau proteinHarald Hampel, Alexander Goernitz, Katharina Buerger
Progress in Neurobiology|September 28, 2011
Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirementsKarl Broich, Marco Weiergräber, Harald Hampel
Molecular Diagnosis & Therapy|June 1, 2011
Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potentialCarmen Noelker, Harald Hampel, Richard Dodel
Neuropsychiatric Disease and Treatment|June 4, 2010
Optimal management of Alzheimer's disease patients: Clinical guidelines and family adviceJulia Haberstroh, Harald Hampel, Johannes Pantel
CNS Neuroscience & Therapeutics|October 21, 2009
Biological marker candidates of Alzheimer's disease in blood, plasma, and serumPhiline Schneider, Harald Hampel, Katharina Buerger
Expert Opinion on Drug Metabolism & Toxicology|February 2, 2010
Galantamine for Alzheimer's diseaseDavid Prvulovic, Harald Hampel, Johannes Pantel
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 27, 2013
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's diseaseKaj Blennow, Harald Hampel, Henrik Zetterberg
Pageof 42